It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Monitoring population protective immunity against SARS-CoV-2 variants is critical for risk assessment. We hypothesize that Hong Kong’s explosive Omicron BA.2 outbreak in early 2022 could be explained by low herd immunity. Our seroprevalence study using sera collected from January to December 2021 shows a very low prevalence of neutralizing antibodies (NAb) against ancestral virus among older adults. The age group-specific prevalence of NAb generally correlates with the vaccination uptake rate, but older adults have a much lower NAb seropositive rate than vaccination uptake rate. For all age groups, the seroprevalence of NAb against Omicron variant is much lower than that against the ancestral virus. Our study suggests that this BA.2 outbreak and the exceptionally high case-fatality rate in the ≥80 year-old age group (9.2%) could be attributed to the lack of protective immunity in the population, especially among the vulnerable older adults, and that ongoing sero-surveillance is essential.
Hong Kong experienced a severe wave of SARS-CoV-2 in early 2022. Here, the authors use genomic and serosurveillance data and show that this wave was dominated by the Omicron BA.2 sublineage, and that low protective immunity, particularly in older age groups, contributed to its severity.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details





1 The University of Hong Kong, State Key Laboratory for Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, Pokfulam, Hong Kong SAR, China (GRID:grid.194645.b) (ISNI:0000000121742757)
2 Quality and Safety Division, Hospital Authority, Hong Kong SAR, China (GRID:grid.414370.5) (ISNI:0000 0004 1764 4320)
3 Centre for Health Protection, Department of Health, Hong Kong SAR, China (GRID:grid.461944.a) (ISNI:0000 0004 1790 898X)
4 The University of Hong Kong, State Key Laboratory for Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, Pokfulam, Hong Kong SAR, China (GRID:grid.194645.b) (ISNI:0000000121742757); Queen Mary Hospital, Pokfulam, Department of Microbiology, Hong Kong SAR, China (GRID:grid.415550.0) (ISNI:0000 0004 1764 4144); Infection Control Team, Queen Mary Hospital, Hong Kong West Cluster, Hong Kong SAR, China (GRID:grid.415550.0) (ISNI:0000 0004 1764 4144)
5 The University of Hong Kong, State Key Laboratory for Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, Pokfulam, Hong Kong SAR, China (GRID:grid.194645.b) (ISNI:0000000121742757); Queen Mary Hospital, Pokfulam, Department of Microbiology, Hong Kong SAR, China (GRID:grid.415550.0) (ISNI:0000 0004 1764 4144); The University of Hong Kong-Shenzhen Hospital, Department of Clinical Microbiology and Infection Control, Shenzhen, China (GRID:grid.440671.0) (ISNI:0000 0004 5373 5131)
6 The University of Hong Kong, State Key Laboratory for Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, Pokfulam, Hong Kong SAR, China (GRID:grid.194645.b) (ISNI:0000000121742757); Queen Mary Hospital, Pokfulam, Department of Microbiology, Hong Kong SAR, China (GRID:grid.415550.0) (ISNI:0000 0004 1764 4144); The University of Hong Kong-Shenzhen Hospital, Department of Clinical Microbiology and Infection Control, Shenzhen, China (GRID:grid.440671.0) (ISNI:0000 0004 5373 5131); Hong Kong Science and Technology Park, Centre for Virology, Vaccinology and Therapeutics, Hong Kong SAR, China (GRID:grid.440671.0)
7 The University of Hong Kong, Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, Pokfulam, Hong Kong SAR, China (GRID:grid.194645.b) (ISNI:0000000121742757)
8 The University of Hong Kong, State Key Laboratory for Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, Pokfulam, Hong Kong SAR, China (GRID:grid.194645.b) (ISNI:0000000121742757); The University of Hong Kong-Shenzhen Hospital, Department of Clinical Microbiology and Infection Control, Shenzhen, China (GRID:grid.440671.0) (ISNI:0000 0004 5373 5131)